ReviewNature reviews. Nephrology2018
Cancer in kidney transplant recipients.
Review in Nature reviews. Nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 111 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
111 citing papers in PubMed, 3 syntheses or guidelines pooled it, 262 citations in OpenAlex.
- De novo colorectal cancer after kidney transplantation: a systematic review and meta-analysis.British journal of cancer · 2025Pooled it
- Incidence of renal cell carcinoma after solid organ transplantation: a systematic review and meta-analysis.BMC urology · 2024Pooled it
- Induction therapy with mesenchymal stromal cells in kidney transplantation: a meta-analysis.Stem cell research & therapy · 2021Pooled it
- The Imbalance Between Tumor Immunosurveillance and Tumor Immune Escape in Glioblastoma.Immunology and cell biology · 2026Review
- The State of Posttransplant Malignancies in Vascularized Composite Allotransplantation.Plastic and reconstructive surgery. Global open · 2026Article
- Cancer Treatment with Immune Checkpoint Inhibition in Solid Organ Transplant Recipients in Switzerland.Cancers · 2026Article
- Association of remnant cholesterol with long-term outcomes in kidney transplant recipients: a retrospective cohort study.Lipids in health and disease · 2026Article
- Renal Cell Carcinoma of Native Kidneys in Kidney Allograft Recipients: Are There Any Guidelines for Management?Journal of clinical medicine · 2026Article
- Pan-cancer polygenic risk score associates with cancer susceptibility following kidney transplantation.JCI insight · 2026Article
- Targeting tumor dormancy: the next frontier in gastrointestinal stromal tumor therapy.Neoplasia (New York, N.Y.) · 2026Review
- Kidney Transplant Recipients: Viral Infections and Malignancies.Pathogens (Basel, Switzerland) · 2026Observational
- Beyond Immunosuppression: Defining Perioperative Risk in Transplant Patients Undergoing Colorectal and Small Bowel Surgery.World journal of surgery · 2026Article
- Article
- Perinephric Myxoid Pseudotumor of Fat: Case Series, Systematic Review of the Literature, Clinical Classification, and Treatment Implications.Kidney medicine · 2026Article
- Incidence and outcomes of malignancies in renal transplant recipients: a 57-year single-center experience.World journal of urology · 2026Article
- Post-transplant malignancies in Taiwanese kidney transplant recipients: incidence, temporal trends, and immunosuppressive risk factors in a two-decade single-center cohort.Frontiers in immunology · 2026Article
- Clinical management of cancer after kidney transplantation.Frontiers in immunology · 2026Review
- Kidney transplantation beyond immunosuppression: shifting the focus from graft survival to patient health.Frontiers in immunology · 2026Review
- Establishing a core outcome measure for cancer in trials in kidney transplantation: a standardized outcomes in nephrology-kidney transplantation consensus workshop report.Transplant international : official journal of the European Society for Organ Transplantation · 2026Article
- Epidemiological Overview of Colorectal Cancer in Kidney Transplant Recipients: A Systematic Review.Cancers · 2025Review
51 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer is the second most common cause of mortality and morbidity in kidney transplant recipients after cardiovascular disease. Kidney transplant recipients have at least a twofold higher risk of developing or dying from cancer than the general population. The increased risk of de novo and recurrent cancer in transplant recipients is multifactorial and attributed to oncogenic viruses, immunosuppression and altered T cell immunity. Transplant candidates and potential donors should be screened for cancer as part of the assessment process. For potential recipients with a prior history of cancer, waiting periods of 2-5 years after remission - largely depending on the cancer type and stage of initial cancer diagnosis - are recommended. Post-transplantation cancer screening needs to be tailored to the individual patient, considering the cancer risk of the individual, comorbidities, overall prognosis and the screening preferences of the patient. In kidney transplant recipients diagnosed with cancer, treatment includes conventional approaches, such as radiotherapy and chemotherapy, together with consideration of altering immunosuppression. As the benefits of transplantation compared with dialysis in potential transplant candidates with a history of cancer have not been assessed, current clinical practice relies on evidence from observational studies and registry analyses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.